Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 12;13:1179558119872490. doi: 10.1177/1179558119872490

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Schematic cartoon summarizing the possible future beneficial effects of various agents in minimizing the gonadotoxic effect of chemotherapy. In addition to the present modalities of GnRHa co-administration, cryopreservation of embryos, ova, or ovarian tissue, future endeavors may consist of the generation of gametes from induced pluripotent stem cells (iPC), in vitro maturation (IVM) of PMFs stored in the cryopreserved ovarian tissue, generation of an in vitro “artificial ovary,” and use of many possible agents. Such possible protective agents include AMH, tamoxifen, melatonin, Shilajit, resveratrol, imatinib (Gleevec), mangafodipir, sphingosine-1-phosphate (S1P), AS101, ceramide-1-phosphate (C1P), granulocyte colony-stimulating factor (G-CSF), dexrazoxane, and possibly others (???). AMH indicates anti-Müllerian hormone.